Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Идиопатическая внутричерепная гипертензия и место ацетазоламида в лечении
Идиопатическая внутричерепная гипертензия и место ацетазоламида в лечении
Пизова Н.В. Идиопатическая внутричерепная гипертензия и место ацетазоламида в лечении. Consilium Medicum. Неврология и Ревматология (Прил.). 2016; 1: 60–64.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье рассмотрены вопросы распространенности, клиники, диагностики и лечения идиопатической внутричерепной гипертензии (ИВЧГ). Обсуждены вопросы ликворообразования и ликвородинамики. Более углубленно в качестве терапевтических воздействий показаны возможности препарата ацетазоламида, который в настоящее время считается основой фармакологического лечения ИВЧГ. Представлены результаты многоцентрового двойного слепого рандомизированного плацебо-контролируемого клинического исследования применения ацетазоламида при данном заболевании в течение 6 мес. Показан профиль безопасности ацетазоламида при терапии пациентов с ИВЧГ.
Ключевые слова: идиопатическая внутричерепная гипертензия, ликворообразование, ликвородинамика, ацетазоламид.
Key words: idiopathic intracranial hypertension, liquor formation, liquorodynamics, acetazolamide.
Ключевые слова: идиопатическая внутричерепная гипертензия, ликворообразование, ликвородинамика, ацетазоламид.
________________________________________________
Key words: idiopathic intracranial hypertension, liquor formation, liquorodynamics, acetazolamide.
Полный текст
Список литературы
1. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 2013; 81: 1159–65.
2. Corbett JJ, Savino PJ, Thompson HS et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39: 461–74.
3. Best J, Silvestri G, Burton B et al. The incidence of blindness due to idiopathic intracranial hypertension in the UK. Open Ophthalmol J 2013; 7: 26–9.
4. Amico D, Curone M, Ciasca P et al. Headache prevalence and clinical features in patients with idiopathic intracranial hypertension (IIH). Neurol Sci 2013; 34 (Suppl. 1): S147–9.
5. Radhakrishnan K, Thacker AK, Bohlaga NH et al. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. J Neurol Sci 1993; 116: 18–28.
6. Curry WT Jr, Butler WE, Barker FG II. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988–2002. Neurosurgery 2005; 57: 97–108.
7. McCluskey G, Mulholland DA, McCarron P et al. Idiopathic intracranial hypertension in the northwest of northern Ireland: epidemiology and clinical management. Neuroepidemiology 2015; 45: 34–9.
8. Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr 2014; 81: 217–25.
9. Nonne M. Über, Fälle vom. Symptomkomplex ‘tumor cerebri’ mit Ausgang in Heillung (Pseudotumor cerebri). Über Letal Verlaufene Fälle von ‘Pseudotumor Cerebri’ mit Sektionsbefund. Dtsch Z Nervenheilkd 1904; 27: 169–216.
10. Dandy WE. Intracranial pressure without brain tumour: diagnosis and treatment. Ann Surg 1937; 106: 492–513.
11. Cserr HF. Role of secretion and bulk flow of brain interstitial fluid in brain volume regulation. Ann N Y Acad Sci 1988; 529: 9–20.
12. Johanson CE, Duncan JA III, Klinge PM et al. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 2008; 5: 10.
13. Malm J, Kristensen B, Markgren P et al. CSF hydrodynamics in idiopathic intracranial hypertension: a long-term study. Neurology 1992; 42: 851–8.
14. Johnston M, Zakharov A, Papaiconomou C et al. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 2004; 1: 2.
15. Louveau A, Smirnov I, Keyes TJ et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523: 337–41.
16. Strahle J, Garton HJ, Maher CO et al. Mechanisms of hydrocephalus after neonatal and adult intraventricular hemorrhage. Transl Stroke Res 2012; 3 (Suppl. 1): 25–38.
17. Iliff JJ, Wang M, Liao Y et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid b. Sci Transl Med 2012; 4: 147ra11.
18. Orefice G, Celentano L, Scaglione M et al. Radioisotopic cisternography in benign intracranial hypertension of young obese women. A seven-case study and pathogenetic suggestions. Acta Neurol (Napoli) 1992; 14: 39–50.
19. Daniels AB, Liu GT, Volpe NJ et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 2007; 143: 635–41.
20. Ko MW, Chang SC, Ridha MA et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology 2011; 76: 1564–7.
21. Johnson LN, Krohel GB, Madsen RW et al. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998; 105: 2313–17.
22. Sinclair AJ, Burdon MA, Nightingale PG et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010; 341: c2701.
23. Guidetti B, Giuffrè R, Gambacorta D. Follow-up study of 100 cases of pseudotumor cerebri. Acta Neurochir (Wien) 1968; 18: 259–67.
24. Huna-Baron R, Kupersmith MJ. Idiopathic intracranial hypertension in pregnancy. J Neurol 2002; 249 (8): 1078–81.
25. Sinclair AJ, Ball AK, Burdon MA et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol 2008; 201–2: 212–20.
26. Toscano V, Sancesario G, Bianchi P et al. Cerebrospinal fluid estrone in pseudotumor cerebri: a change in cerebral steroid hormone metabolism? J Endocrinol Invest 1991; 14: 81–6.
27. Klein A, Stern N, Osher E et al. Hyperandrogenism is associated with earlier age of onset of idiopathic intracranial hypertension in women. Curr Eye Res 2013; 38: 972–6.
28. Riggeal BD, Bruce BB, Saindane AM et al. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology 2013; 80: 289–95.
29. Farb RI, Vanek I, Scott JN et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60: 1418–24.
30. Corbett JJ, Savino PJ, Thompson HS et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39: 461–74.
31. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 (Pt 1A): 155–80.
32. Thambisetty M, Lavin PJ, Newman NJ et al. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68: 229–32.
33. Yri HM, Rönnbäck C, Wegener M et al. The course of headache in idiopathic intracranial hypertension: a 12-month prospective follow-up study. Eur J Neurol 2014; 21: 1458–64.
34. Wall M, Kupersmith MJ, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014; 71: 693–701.
35. Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin 2014; 32: 363–96.
36. Wall M, Kupersmith MJ, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014; 71: 693–701.
37. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59 (10): 1492–5.
38. Brodsky MC, Vaphiades M. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology 1998; 105: 1686–93.
39. Mollan SP, Markey KA, Benzimra JD et al. A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension. Pract Neurol 2014; 14: 380–90.
40. Glueck CJ, Aregawi DA, Goldenberg N et al. Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. J Lab Clin Med 2005; 145: 72–82.
41. Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med 1974; 133: 802–7.
42. Kupersmith MJ, Gamell L, Turbin R et al. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology 1998; 50: 1094–8.
43. Wong R, Madill SA, Pandey P et al. Idiopathic intracranial hypertension: the association between weight loss and the requirement for systemic treatment. BMC Ophthalmol 2007; 7: 15.
44. Maren TH. Carbonic Anhydrase: chemistry, physiology and inhibition. Physiol Rev 1967; 47: 595–781.
45. Becker B, Middleton WH. Long-term acetazoleamide (diamox) administration in therapy of glaucomas. AMA Arch Ophthalmol 1955; 54: 187–92.
46. Reynolds JEF (ed). Martindale: The Extra Pharmacopoeia. London: The Pharmaceuical Press, 1993.
47. Lubow M, Kuhr L. Pseudotumor cerebri: comments on practical management. In: Glaser JS, Smith JL, editors. Neuro-ophthalmology. Vol. IX. St. Louis, MO: CV Mosby, 1976; p. 199–206.
48. Tomsak RL, Niffenegger AS, Remler BF. Treatment of pseudotumor cerebri with Diamox (acetazolamide). J Clin Neuroophthalmol 1988; 8: 93–8.
49. Gücer G, Viernstein L. Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg 1978; 49 (2): 256–63.
50. Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005; 3: CD003434.
51. Piper RJ, Kalyvas AV, Young AM et al. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2015; 8: CD003434.
52. Wall M, McDermott MP, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014; 311 (16): 1641–51.
53. Celebisoy N, Gökçay F, Sirin H et al. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116: 322–7.
54. De Simone R, Marano E, Fiorillo C et al. Sudden re-opening of collapsed transverse sinuses and longstanding clinical remission after a single lumbar puncture in a case of idiopathic intracranial hypertension. Pathogenetic implications. Neurol Sci 2005; 25: 342–4.
55. Satti SR, Leishangthem L, Chaudry MI. Meta-analysis of CSF diversion procedures and dural venous sinus stenting in the setting of medically refractory idiopathic intracranial hypertension. AJNR Am J Neuroradiol 2015; 36: 1899–904.
56. Fonseca PL, Rigamonti D, Miller NR et al. Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion. Br J Ophthalmol 2014; 98: 1360–3.
57. Sinclair AJ, Kuruvath S, Sen D et al. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia 2011; 31: 1627–33.
58. Teleb MS, Cziep ME, Issa M et al. Stenting and angioplasty for idiopathic intracranial hypertension: a case series with clinical, angiographic, ophthalmological, complication, and pressure reporting. J Neuroimaging 2015; 25: 72–80.
59. Teleb MS, Cziep ME, Lazzaro MA et al. Idiopathic intracranial hypertension. A systematic analysis of transverse sinus stenting. Interv Neurol 2013; 2: 132–43.
2. Corbett JJ, Savino PJ, Thompson HS et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39: 461–74.
3. Best J, Silvestri G, Burton B et al. The incidence of blindness due to idiopathic intracranial hypertension in the UK. Open Ophthalmol J 2013; 7: 26–9.
4. Amico D, Curone M, Ciasca P et al. Headache prevalence and clinical features in patients with idiopathic intracranial hypertension (IIH). Neurol Sci 2013; 34 (Suppl. 1): S147–9.
5. Radhakrishnan K, Thacker AK, Bohlaga NH et al. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. J Neurol Sci 1993; 116: 18–28.
6. Curry WT Jr, Butler WE, Barker FG II. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988–2002. Neurosurgery 2005; 57: 97–108.
7. McCluskey G, Mulholland DA, McCarron P et al. Idiopathic intracranial hypertension in the northwest of northern Ireland: epidemiology and clinical management. Neuroepidemiology 2015; 45: 34–9.
8. Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr 2014; 81: 217–25.
9. Nonne M. Über, Fälle vom. Symptomkomplex ‘tumor cerebri’ mit Ausgang in Heillung (Pseudotumor cerebri). Über Letal Verlaufene Fälle von ‘Pseudotumor Cerebri’ mit Sektionsbefund. Dtsch Z Nervenheilkd 1904; 27: 169–216.
10. Dandy WE. Intracranial pressure without brain tumour: diagnosis and treatment. Ann Surg 1937; 106: 492–513.
11. Cserr HF. Role of secretion and bulk flow of brain interstitial fluid in brain volume regulation. Ann N Y Acad Sci 1988; 529: 9–20.
12. Johanson CE, Duncan JA III, Klinge PM et al. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 2008; 5: 10.
13. Malm J, Kristensen B, Markgren P et al. CSF hydrodynamics in idiopathic intracranial hypertension: a long-term study. Neurology 1992; 42: 851–8.
14. Johnston M, Zakharov A, Papaiconomou C et al. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 2004; 1: 2.
15. Louveau A, Smirnov I, Keyes TJ et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523: 337–41.
16. Strahle J, Garton HJ, Maher CO et al. Mechanisms of hydrocephalus after neonatal and adult intraventricular hemorrhage. Transl Stroke Res 2012; 3 (Suppl. 1): 25–38.
17. Iliff JJ, Wang M, Liao Y et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid b. Sci Transl Med 2012; 4: 147ra11.
18. Orefice G, Celentano L, Scaglione M et al. Radioisotopic cisternography in benign intracranial hypertension of young obese women. A seven-case study and pathogenetic suggestions. Acta Neurol (Napoli) 1992; 14: 39–50.
19. Daniels AB, Liu GT, Volpe NJ et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 2007; 143: 635–41.
20. Ko MW, Chang SC, Ridha MA et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology 2011; 76: 1564–7.
21. Johnson LN, Krohel GB, Madsen RW et al. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998; 105: 2313–17.
22. Sinclair AJ, Burdon MA, Nightingale PG et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010; 341: c2701.
23. Guidetti B, Giuffrè R, Gambacorta D. Follow-up study of 100 cases of pseudotumor cerebri. Acta Neurochir (Wien) 1968; 18: 259–67.
24. Huna-Baron R, Kupersmith MJ. Idiopathic intracranial hypertension in pregnancy. J Neurol 2002; 249 (8): 1078–81.
25. Sinclair AJ, Ball AK, Burdon MA et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol 2008; 201–2: 212–20.
26. Toscano V, Sancesario G, Bianchi P et al. Cerebrospinal fluid estrone in pseudotumor cerebri: a change in cerebral steroid hormone metabolism? J Endocrinol Invest 1991; 14: 81–6.
27. Klein A, Stern N, Osher E et al. Hyperandrogenism is associated with earlier age of onset of idiopathic intracranial hypertension in women. Curr Eye Res 2013; 38: 972–6.
28. Riggeal BD, Bruce BB, Saindane AM et al. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology 2013; 80: 289–95.
29. Farb RI, Vanek I, Scott JN et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60: 1418–24.
30. Corbett JJ, Savino PJ, Thompson HS et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39: 461–74.
31. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 (Pt 1A): 155–80.
32. Thambisetty M, Lavin PJ, Newman NJ et al. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68: 229–32.
33. Yri HM, Rönnbäck C, Wegener M et al. The course of headache in idiopathic intracranial hypertension: a 12-month prospective follow-up study. Eur J Neurol 2014; 21: 1458–64.
34. Wall M, Kupersmith MJ, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014; 71: 693–701.
35. Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin 2014; 32: 363–96.
36. Wall M, Kupersmith MJ, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014; 71: 693–701.
37. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59 (10): 1492–5.
38. Brodsky MC, Vaphiades M. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology 1998; 105: 1686–93.
39. Mollan SP, Markey KA, Benzimra JD et al. A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension. Pract Neurol 2014; 14: 380–90.
40. Glueck CJ, Aregawi DA, Goldenberg N et al. Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. J Lab Clin Med 2005; 145: 72–82.
41. Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med 1974; 133: 802–7.
42. Kupersmith MJ, Gamell L, Turbin R et al. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology 1998; 50: 1094–8.
43. Wong R, Madill SA, Pandey P et al. Idiopathic intracranial hypertension: the association between weight loss and the requirement for systemic treatment. BMC Ophthalmol 2007; 7: 15.
44. Maren TH. Carbonic Anhydrase: chemistry, physiology and inhibition. Physiol Rev 1967; 47: 595–781.
45. Becker B, Middleton WH. Long-term acetazoleamide (diamox) administration in therapy of glaucomas. AMA Arch Ophthalmol 1955; 54: 187–92.
46. Reynolds JEF (ed). Martindale: The Extra Pharmacopoeia. London: The Pharmaceuical Press, 1993.
47. Lubow M, Kuhr L. Pseudotumor cerebri: comments on practical management. In: Glaser JS, Smith JL, editors. Neuro-ophthalmology. Vol. IX. St. Louis, MO: CV Mosby, 1976; p. 199–206.
48. Tomsak RL, Niffenegger AS, Remler BF. Treatment of pseudotumor cerebri with Diamox (acetazolamide). J Clin Neuroophthalmol 1988; 8: 93–8.
49. Gücer G, Viernstein L. Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg 1978; 49 (2): 256–63.
50. Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005; 3: CD003434.
51. Piper RJ, Kalyvas AV, Young AM et al. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2015; 8: CD003434.
52. Wall M, McDermott MP, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014; 311 (16): 1641–51.
53. Celebisoy N, Gökçay F, Sirin H et al. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116: 322–7.
54. De Simone R, Marano E, Fiorillo C et al. Sudden re-opening of collapsed transverse sinuses and longstanding clinical remission after a single lumbar puncture in a case of idiopathic intracranial hypertension. Pathogenetic implications. Neurol Sci 2005; 25: 342–4.
55. Satti SR, Leishangthem L, Chaudry MI. Meta-analysis of CSF diversion procedures and dural venous sinus stenting in the setting of medically refractory idiopathic intracranial hypertension. AJNR Am J Neuroradiol 2015; 36: 1899–904.
56. Fonseca PL, Rigamonti D, Miller NR et al. Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion. Br J Ophthalmol 2014; 98: 1360–3.
57. Sinclair AJ, Kuruvath S, Sen D et al. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia 2011; 31: 1627–33.
58. Teleb MS, Cziep ME, Issa M et al. Stenting and angioplasty for idiopathic intracranial hypertension: a case series with clinical, angiographic, ophthalmological, complication, and pressure reporting. J Neuroimaging 2015; 25: 72–80.
59. Teleb MS, Cziep ME, Lazzaro MA et al. Idiopathic intracranial hypertension. A systematic analysis of transverse sinus stenting. Interv Neurol 2013; 2: 132–43.
2. Corbett JJ, Savino PJ, Thompson HS et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39: 461–74.
3. Best J, Silvestri G, Burton B et al. The incidence of blindness due to idiopathic intracranial hypertension in the UK. Open Ophthalmol J 2013; 7: 26–9.
4. Amico D, Curone M, Ciasca P et al. Headache prevalence and clinical features in patients with idiopathic intracranial hypertension (IIH). Neurol Sci 2013; 34 (Suppl. 1): S147–9.
5. Radhakrishnan K, Thacker AK, Bohlaga NH et al. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. J Neurol Sci 1993; 116: 18–28.
6. Curry WT Jr, Butler WE, Barker FG II. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988–2002. Neurosurgery 2005; 57: 97–108.
7. McCluskey G, Mulholland DA, McCarron P et al. Idiopathic intracranial hypertension in the northwest of northern Ireland: epidemiology and clinical management. Neuroepidemiology 2015; 45: 34–9.
8. Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr 2014; 81: 217–25.
9. Nonne M. Über, Fälle vom. Symptomkomplex ‘tumor cerebri’ mit Ausgang in Heillung (Pseudotumor cerebri). Über Letal Verlaufene Fälle von ‘Pseudotumor Cerebri’ mit Sektionsbefund. Dtsch Z Nervenheilkd 1904; 27: 169–216.
10. Dandy WE. Intracranial pressure without brain tumour: diagnosis and treatment. Ann Surg 1937; 106: 492–513.
11. Cserr HF. Role of secretion and bulk flow of brain interstitial fluid in brain volume regulation. Ann N Y Acad Sci 1988; 529: 9–20.
12. Johanson CE, Duncan JA III, Klinge PM et al. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 2008; 5: 10.
13. Malm J, Kristensen B, Markgren P et al. CSF hydrodynamics in idiopathic intracranial hypertension: a long-term study. Neurology 1992; 42: 851–8.
14. Johnston M, Zakharov A, Papaiconomou C et al. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 2004; 1: 2.
15. Louveau A, Smirnov I, Keyes TJ et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523: 337–41.
16. Strahle J, Garton HJ, Maher CO et al. Mechanisms of hydrocephalus after neonatal and adult intraventricular hemorrhage. Transl Stroke Res 2012; 3 (Suppl. 1): 25–38.
17. Iliff JJ, Wang M, Liao Y et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid b. Sci Transl Med 2012; 4: 147ra11.
18. Orefice G, Celentano L, Scaglione M et al. Radioisotopic cisternography in benign intracranial hypertension of young obese women. A seven-case study and pathogenetic suggestions. Acta Neurol (Napoli) 1992; 14: 39–50.
19. Daniels AB, Liu GT, Volpe NJ et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 2007; 143: 635–41.
20. Ko MW, Chang SC, Ridha MA et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology 2011; 76: 1564–7.
21. Johnson LN, Krohel GB, Madsen RW et al. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998; 105: 2313–17.
22. Sinclair AJ, Burdon MA, Nightingale PG et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010; 341: c2701.
23. Guidetti B, Giuffrè R, Gambacorta D. Follow-up study of 100 cases of pseudotumor cerebri. Acta Neurochir (Wien) 1968; 18: 259–67.
24. Huna-Baron R, Kupersmith MJ. Idiopathic intracranial hypertension in pregnancy. J Neurol 2002; 249 (8): 1078–81.
25. Sinclair AJ, Ball AK, Burdon MA et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol 2008; 201–2: 212–20.
26. Toscano V, Sancesario G, Bianchi P et al. Cerebrospinal fluid estrone in pseudotumor cerebri: a change in cerebral steroid hormone metabolism? J Endocrinol Invest 1991; 14: 81–6.
27. Klein A, Stern N, Osher E et al. Hyperandrogenism is associated with earlier age of onset of idiopathic intracranial hypertension in women. Curr Eye Res 2013; 38: 972–6.
28. Riggeal BD, Bruce BB, Saindane AM et al. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology 2013; 80: 289–95.
29. Farb RI, Vanek I, Scott JN et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60: 1418–24.
30. Corbett JJ, Savino PJ, Thompson HS et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39: 461–74.
31. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 (Pt 1A): 155–80.
32. Thambisetty M, Lavin PJ, Newman NJ et al. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68: 229–32.
33. Yri HM, Rönnbäck C, Wegener M et al. The course of headache in idiopathic intracranial hypertension: a 12-month prospective follow-up study. Eur J Neurol 2014; 21: 1458–64.
34. Wall M, Kupersmith MJ, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014; 71: 693–701.
35. Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin 2014; 32: 363–96.
36. Wall M, Kupersmith MJ, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014; 71: 693–701.
37. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59 (10): 1492–5.
38. Brodsky MC, Vaphiades M. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology 1998; 105: 1686–93.
39. Mollan SP, Markey KA, Benzimra JD et al. A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension. Pract Neurol 2014; 14: 380–90.
40. Glueck CJ, Aregawi DA, Goldenberg N et al. Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. J Lab Clin Med 2005; 145: 72–82.
41. Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med 1974; 133: 802–7.
42. Kupersmith MJ, Gamell L, Turbin R et al. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology 1998; 50: 1094–8.
43. Wong R, Madill SA, Pandey P et al. Idiopathic intracranial hypertension: the association between weight loss and the requirement for systemic treatment. BMC Ophthalmol 2007; 7: 15.
44. Maren TH. Carbonic Anhydrase: chemistry, physiology and inhibition. Physiol Rev 1967; 47: 595–781.
45. Becker B, Middleton WH. Long-term acetazoleamide (diamox) administration in therapy of glaucomas. AMA Arch Ophthalmol 1955; 54: 187–92.
46. Reynolds JEF (ed). Martindale: The Extra Pharmacopoeia. London: The Pharmaceuical Press, 1993.
47. Lubow M, Kuhr L. Pseudotumor cerebri: comments on practical management. In: Glaser JS, Smith JL, editors. Neuro-ophthalmology. Vol. IX. St. Louis, MO: CV Mosby, 1976; p. 199–206.
48. Tomsak RL, Niffenegger AS, Remler BF. Treatment of pseudotumor cerebri with Diamox (acetazolamide). J Clin Neuroophthalmol 1988; 8: 93–8.
49. Gücer G, Viernstein L. Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg 1978; 49 (2): 256–63.
50. Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005; 3: CD003434.
51. Piper RJ, Kalyvas AV, Young AM et al. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2015; 8: CD003434.
52. Wall M, McDermott MP, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014; 311 (16): 1641–51.
53. Celebisoy N, Gökçay F, Sirin H et al. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116: 322–7.
54. De Simone R, Marano E, Fiorillo C et al. Sudden re-opening of collapsed transverse sinuses and longstanding clinical remission after a single lumbar puncture in a case of idiopathic intracranial hypertension. Pathogenetic implications. Neurol Sci 2005; 25: 342–4.
55. Satti SR, Leishangthem L, Chaudry MI. Meta-analysis of CSF diversion procedures and dural venous sinus stenting in the setting of medically refractory idiopathic intracranial hypertension. AJNR Am J Neuroradiol 2015; 36: 1899–904.
56. Fonseca PL, Rigamonti D, Miller NR et al. Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion. Br J Ophthalmol 2014; 98: 1360–3.
57. Sinclair AJ, Kuruvath S, Sen D et al. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia 2011; 31: 1627–33.
58. Teleb MS, Cziep ME, Issa M et al. Stenting and angioplasty for idiopathic intracranial hypertension: a case series with clinical, angiographic, ophthalmological, complication, and pressure reporting. J Neuroimaging 2015; 25: 72–80.
59. Teleb MS, Cziep ME, Lazzaro MA et al. Idiopathic intracranial hypertension. A systematic analysis of transverse sinus stenting. Interv Neurol 2013; 2: 132–43.
________________________________________________
2. Corbett JJ, Savino PJ, Thompson HS et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39: 461–74.
3. Best J, Silvestri G, Burton B et al. The incidence of blindness due to idiopathic intracranial hypertension in the UK. Open Ophthalmol J 2013; 7: 26–9.
4. Amico D, Curone M, Ciasca P et al. Headache prevalence and clinical features in patients with idiopathic intracranial hypertension (IIH). Neurol Sci 2013; 34 (Suppl. 1): S147–9.
5. Radhakrishnan K, Thacker AK, Bohlaga NH et al. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. J Neurol Sci 1993; 116: 18–28.
6. Curry WT Jr, Butler WE, Barker FG II. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988–2002. Neurosurgery 2005; 57: 97–108.
7. McCluskey G, Mulholland DA, McCarron P et al. Idiopathic intracranial hypertension in the northwest of northern Ireland: epidemiology and clinical management. Neuroepidemiology 2015; 45: 34–9.
8. Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr 2014; 81: 217–25.
9. Nonne M. Über, Fälle vom. Symptomkomplex ‘tumor cerebri’ mit Ausgang in Heillung (Pseudotumor cerebri). Über Letal Verlaufene Fälle von ‘Pseudotumor Cerebri’ mit Sektionsbefund. Dtsch Z Nervenheilkd 1904; 27: 169–216.
10. Dandy WE. Intracranial pressure without brain tumour: diagnosis and treatment. Ann Surg 1937; 106: 492–513.
11. Cserr HF. Role of secretion and bulk flow of brain interstitial fluid in brain volume regulation. Ann N Y Acad Sci 1988; 529: 9–20.
12. Johanson CE, Duncan JA III, Klinge PM et al. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 2008; 5: 10.
13. Malm J, Kristensen B, Markgren P et al. CSF hydrodynamics in idiopathic intracranial hypertension: a long-term study. Neurology 1992; 42: 851–8.
14. Johnston M, Zakharov A, Papaiconomou C et al. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 2004; 1: 2.
15. Louveau A, Smirnov I, Keyes TJ et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523: 337–41.
16. Strahle J, Garton HJ, Maher CO et al. Mechanisms of hydrocephalus after neonatal and adult intraventricular hemorrhage. Transl Stroke Res 2012; 3 (Suppl. 1): 25–38.
17. Iliff JJ, Wang M, Liao Y et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid b. Sci Transl Med 2012; 4: 147ra11.
18. Orefice G, Celentano L, Scaglione M et al. Radioisotopic cisternography in benign intracranial hypertension of young obese women. A seven-case study and pathogenetic suggestions. Acta Neurol (Napoli) 1992; 14: 39–50.
19. Daniels AB, Liu GT, Volpe NJ et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 2007; 143: 635–41.
20. Ko MW, Chang SC, Ridha MA et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology 2011; 76: 1564–7.
21. Johnson LN, Krohel GB, Madsen RW et al. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998; 105: 2313–17.
22. Sinclair AJ, Burdon MA, Nightingale PG et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010; 341: c2701.
23. Guidetti B, Giuffrè R, Gambacorta D. Follow-up study of 100 cases of pseudotumor cerebri. Acta Neurochir (Wien) 1968; 18: 259–67.
24. Huna-Baron R, Kupersmith MJ. Idiopathic intracranial hypertension in pregnancy. J Neurol 2002; 249 (8): 1078–81.
25. Sinclair AJ, Ball AK, Burdon MA et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol 2008; 201–2: 212–20.
26. Toscano V, Sancesario G, Bianchi P et al. Cerebrospinal fluid estrone in pseudotumor cerebri: a change in cerebral steroid hormone metabolism? J Endocrinol Invest 1991; 14: 81–6.
27. Klein A, Stern N, Osher E et al. Hyperandrogenism is associated with earlier age of onset of idiopathic intracranial hypertension in women. Curr Eye Res 2013; 38: 972–6.
28. Riggeal BD, Bruce BB, Saindane AM et al. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology 2013; 80: 289–95.
29. Farb RI, Vanek I, Scott JN et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60: 1418–24.
30. Corbett JJ, Savino PJ, Thompson HS et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39: 461–74.
31. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 (Pt 1A): 155–80.
32. Thambisetty M, Lavin PJ, Newman NJ et al. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68: 229–32.
33. Yri HM, Rönnbäck C, Wegener M et al. The course of headache in idiopathic intracranial hypertension: a 12-month prospective follow-up study. Eur J Neurol 2014; 21: 1458–64.
34. Wall M, Kupersmith MJ, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014; 71: 693–701.
35. Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin 2014; 32: 363–96.
36. Wall M, Kupersmith MJ, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014; 71: 693–701.
37. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59 (10): 1492–5.
38. Brodsky MC, Vaphiades M. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology 1998; 105: 1686–93.
39. Mollan SP, Markey KA, Benzimra JD et al. A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension. Pract Neurol 2014; 14: 380–90.
40. Glueck CJ, Aregawi DA, Goldenberg N et al. Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. J Lab Clin Med 2005; 145: 72–82.
41. Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med 1974; 133: 802–7.
42. Kupersmith MJ, Gamell L, Turbin R et al. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology 1998; 50: 1094–8.
43. Wong R, Madill SA, Pandey P et al. Idiopathic intracranial hypertension: the association between weight loss and the requirement for systemic treatment. BMC Ophthalmol 2007; 7: 15.
44. Maren TH. Carbonic Anhydrase: chemistry, physiology and inhibition. Physiol Rev 1967; 47: 595–781.
45. Becker B, Middleton WH. Long-term acetazoleamide (diamox) administration in therapy of glaucomas. AMA Arch Ophthalmol 1955; 54: 187–92.
46. Reynolds JEF (ed). Martindale: The Extra Pharmacopoeia. London: The Pharmaceuical Press, 1993.
47. Lubow M, Kuhr L. Pseudotumor cerebri: comments on practical management. In: Glaser JS, Smith JL, editors. Neuro-ophthalmology. Vol. IX. St. Louis, MO: CV Mosby, 1976; p. 199–206.
48. Tomsak RL, Niffenegger AS, Remler BF. Treatment of pseudotumor cerebri with Diamox (acetazolamide). J Clin Neuroophthalmol 1988; 8: 93–8.
49. Gücer G, Viernstein L. Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg 1978; 49 (2): 256–63.
50. Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005; 3: CD003434.
51. Piper RJ, Kalyvas AV, Young AM et al. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2015; 8: CD003434.
52. Wall M, McDermott MP, Kieburtz KD et al. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014; 311 (16): 1641–51.
53. Celebisoy N, Gökçay F, Sirin H et al. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116: 322–7.
54. De Simone R, Marano E, Fiorillo C et al. Sudden re-opening of collapsed transverse sinuses and longstanding clinical remission after a single lumbar puncture in a case of idiopathic intracranial hypertension. Pathogenetic implications. Neurol Sci 2005; 25: 342–4.
55. Satti SR, Leishangthem L, Chaudry MI. Meta-analysis of CSF diversion procedures and dural venous sinus stenting in the setting of medically refractory idiopathic intracranial hypertension. AJNR Am J Neuroradiol 2015; 36: 1899–904.
56. Fonseca PL, Rigamonti D, Miller NR et al. Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion. Br J Ophthalmol 2014; 98: 1360–3.
57. Sinclair AJ, Kuruvath S, Sen D et al. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia 2011; 31: 1627–33.
58. Teleb MS, Cziep ME, Issa M et al. Stenting and angioplasty for idiopathic intracranial hypertension: a case series with clinical, angiographic, ophthalmological, complication, and pressure reporting. J Neuroimaging 2015; 25: 72–80.
59. Teleb MS, Cziep ME, Lazzaro MA et al. Idiopathic intracranial hypertension. A systematic analysis of transverse sinus stenting. Interv Neurol 2013; 2: 132–43.
Авторы
Н.В.Пизова*
ГБОУ ВПО Ярославский государственный медицинский университет Минздрава России. 150000, Россия, Ярославль, ул. Революционная, д. 5
*pizova@yandex.ru
Yaroslavl State Medical University of the Ministry of Health of the Russian Federation. 150000, Russian Federation, Yaroslavl, ul. Revoliutsionnaia, d. 5
*pizova@yandex.ru
ГБОУ ВПО Ярославский государственный медицинский университет Минздрава России. 150000, Россия, Ярославль, ул. Революционная, д. 5
*pizova@yandex.ru
________________________________________________
Yaroslavl State Medical University of the Ministry of Health of the Russian Federation. 150000, Russian Federation, Yaroslavl, ul. Revoliutsionnaia, d. 5
*pizova@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.